Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection

Authors:

Matthew C. Woodruff[1,3], Richard P. Ramonell[2,3], F. Eun-Hyung Lee[2], Ignacio Sanz[1*]*

Affiliations:

[1]Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA

[2]Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA

[3]These authors contributed equally: Matthew C. Woodruff and Richard P. Ramonell

**Corresponding authors: Drs. F. Eun-Hyung Lee and Ignacio Sanz*

Corresponding Author Contacts:

Dr. Ignacio Sanz, MD, ignacio.sanz@emory.edu; (404) 712-2945

Dr. F. Eun-Hyung Lee, MD, f.e.lee@emory.edu

Abstract

Severe SARS-CoV-2 infection is linked to the presence of autoantibodies against multiple targets, including phospholipids and type-I interferons. We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of *de novo* autoreactive antibody production during the antiviral response. Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation.

Main text

The contribution of B cell responses to severe COVID-19 infection through the generation of pathogenic autoantibodies remains to be demonstrated. Yet, such a mechanism is strongly supported by recent descriptions of autoantibodies against phospholipids[1], type-I interferons[2], and other targets[3]. Our group and others have recently described a correlation between severe infection and intense extra-follicular (EF), B cell responses bearing cellular, repertoire and serological features reminiscent of SLE pathogenic auto-reactivity [4-6]. Together, these observations raised the possibility that severe SARS-CoV-2 infection frequently results in breaks of self-tolerance to a variety of autoantigens.

To explore this possibility, we retrospectively collected data from 31 critically ill patients with COVID-19 and no known history of autoimmunity undergoing treatment between June 1st and July 2nd, 2020 in two academic intensive care units in Atlanta, Georgia, USA. All patients fell into the NIH COVID-19 “Severe” or “Critical” categories with an average CRP level of 191ug/mL (Table 1).

Patients were tested for a variety of broad serologies commonly used for the initial evaluation of autoimmune rheumatic diseases (Table 1). Consistent with tolerance breakdown, 44% of patients had positive levels of ANA at ≥ 1:80, the entry threshold value for SLE classification[7] in a predominantly speckled pattern (50%) (Fig 1a). Of positive tests, 81% displayed titers of ≥1:160, a titer present in <5% of the normal population, with the higher titers ranging from 1:320-1:640(Fig 1a). Anti-RNP and anti-centromere IgG titers were detected in 2 of 22 ANA^+ patients, while dsDNA reactivity was not readily detected (Fig 1a). Reactivity against rheumatoid factor (10/52), phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52), with or without ANA reactivity,

suggests broad autoimmune targeting (Fig 1a). Indeed, 59% of ANA^+ patients displayed at least one other positive auto-reactive antibody test emphasizing the potential for multiple tolerance breaks across the cohort (Table 1, Figure 1a).

The presence of autoreactivity could be clearly correlated with increasing serum levels of CRP (Figure 1a). We have previously described the correlation of serum CRP with the activation of SLE-like B cell responses although those findings stopped short of documenting clinical autoreactivity. In this cohort, we identify increased production of both ANAs (35% vs. 56%, respectively) and RF (0% vs. 38%) in patients with higher CRP levels (Figure 1b), with >70% of patients in the CRP-high group showing ANA or RF production, confirming autoreactivity as a common feature of severe disease. Of importance, all patients displaying additional autoreactivities tested positive for either ANAs, or RF, suggesting that these two clinical tests may be valuable in efficiently screening patients for broad tolerance breaks.

Longitudinal data was available for 7 patients within the cohort at 2-week follow-up. Out of 4+ baseline ANA titers, 2 increased to as high as 1:2560, one remained at 1:360, and a lower 1:80 became negative. Of note, substantial or increasing ANA titers occurred despite declining serum CRP levels (Figure 1c).

Effector B cell responses can proceed either through germinal center reactions or extrafollicular (EF) responses. In both cases, autoreactivity is likely to be generated through activation of autoreactive cells present at high frequency in the pre-antigenic naïve repertoire. While GC reactions frequently generate additional autoreactivity through somatic hypermutation, they are also endowed with multiple checkpoints to prevent their progression to pathogenic effector responses. In contrast, EF reactions are characterized by direct antibody production and may not be able to negatively regulate autoreactive B cell responses [8]. Human EF responses have been best defined in SLE, where they may be induced through TLR7 by single-stranded RNA sensing, and correlate with disease severity[9].

Our findings invite two interpretations. Either patients with undocumented and pre-existing autoimmunity comprise the majority of the critical illness within our Atlanta-based cohort, or more likely, the immunological

environment of serious COVID-19 infection, including TLR7 activation by SARS-CoV2 ssRNA, is sufficient to drive *de novo* autoreactivity against a variety of self-antigens. The latter possibility has been documented in the setting of other serious infections[10], and is now mechanistically supported through independent validation of autoimmune-prone EF response activation in serious disease[6]. These findings may be consequential for the identification of patients in whom immunomodulation may be beneficial and suggest the value of autoreactivity measurements for proper segmentation and allocation of properly targeted therapies. They further suggest that simple clinical testing for ANAs or RF may be able to distinguish those groups. Longitudinal study of recovered patients will be critical in understanding the persistence of this autoreactive state, it's role in the increasingly documented cases of 'lingering' COVID-19[11], and it's propensity for conversion into self-sustaining autoimmunity in order to devise early rheumatological intervention strategies and establish effective long-term care protocols.

References

1. Bowles, L.*, et al.* Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. *N Engl J Med* (2020).
2. Bastard, P.*, et al.* Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science* (2020).
3. Consiglio, C.R.*, et al.* The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. *Cell* (2020).
4. Woodruff, M.C.*, et al.* Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. *Nature immunology* (2020).
5. Tipton, C.M.*, et al.* Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. *Nat Immunol* **16**, 755-765 (2015).
6. Kaneko, N.*, et al.* Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. *Cell* (2020).
7. Aringer, M.*, et al.* 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. **71**, 1400-1412 (2019).
8. Jenks, S.A., Cashman, K.S., Woodruff, M.C., Lee, F.E. & Sanz, I. Extrafollicular responses in humans and SLE. *Immunol Rev* **288**, 136-148 (2019).
9. Jenks, S.A.*, et al.* Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* **49**, 725-739 e726 (2018).
10. Isenberg, D.A.*, et al.* Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections. *Clin Exp Immunol* **67**, 516-523 (1987).
11. Carfi, A., Bernabei, R., Landi, F. & Gemelli Against, C.-P.-A.C.S.G. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **324**, 603-605 (2020).

Acknowledgements

We would like to thank S. Auld, W. Bender, L. Daniels, B. Staitieh, C. Swenson, and A. Truong for their expertise and support of our research. We would also like to thank the nurses, staff, and providers in the 71 ICU in Emory University Hospital Midtown and the 2E ICU in Emory Saint Joseph's Hospital.

Author Contributions

M.C.W and R.P.R contributed equally in writing the manuscript, data analysis and interpretation, and figure design. F. E.-H. L. and I.S. contributed equally in study design, data interpretation, and study support.

Methods

Human Subjects

All research was approved by the Emory University Institutional Review Board (Emory IRB numbers IRB00058507, IRB00057983, and IRB00058271) and was performed in accordance with all relevant guidelines and regulations.

COIs

Dr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech.

Funding sources

This work was supported by National Institutes of Health grants: UL TR000424 (Emory Library IT), U19-AI110483 Emory Autoimmunity Center of Excellence (I.S.), P01-AI125180-01 (I.S., F.E.L.), R37-AI049660 (I.S.), 1R01AI12125 (F.E.L.), 1U01AI141993 (F.E.L), and T32-HL116271-07 (R.P.R.)

Tables

Table 1 – Characteristics of Research Subjects

Characteristic	All Subjects (n = 52)	Reference Range
Age (range) – yr	58±14 (24-90)	–
Gender – no. (%)		
Male	35 (67)	–
Female	17 (33)	
Race – no. (%)		
Caucasian	17 (33)	
African-American	28 (54)	
Asian	3 (6)	–
Other	4 (8)	
Ethnicity – no. (%)		
Hispanic	10 (19)	–
Non-Hispanic	42 (81)	
Time Post Symptom Onset (range) – days	10±6 (2-32)	–
Personal history of autoimmune disease – no. (%)	0 (0)	–
Laboratory Findings		
C-reactive protein (range) – mg/L	174±115 (17-473)	≤ 10
Interleukin 6 (range) – pg/mL[$]	26.3±66.6 (0-424)	≤ 2
Autoantibody Test Results		
Positive – no. (%)		
Anti-nuclear antigen	23 (44)	
Anti-extractable nuclear antigens	2 (4)	
Anti-double stranded DNA**	0 (0)	
Anti-Scl-70**	0 (0)	
Rheumatoid Factor[@]	12 (24)	–
Anti-myeloperoxidase[#]	0 (0)	
Anti-serine proteinase 3[#]	2 (5)	
Anti-cardiolipin IgG[@]	2 (4)	
Anti-B2GP1 IgG[@]	2 (4)	
Anti-prothrombin IgG[@]	2 (4)	
Anti-phosphatidylserine IgG[@]	0 (0)	
Anti-Nuclear Antigen Pattern – no. (%)		
Speckled	11 (48)	
Nucleolar	9 (39)	–
Centromere	1 (4)	
Homogeneous	2 (9)	
Anti-Nuclear Antigen Titer – no. (%)		
1:80	4 (17)	
1:160	11 (48)	–
1:320	4 (17)	
1:640	4 (17)	
> 1:640	0 (0)	
Measures of Complement Consumption		
C3 Level – mg/dL	127±33 (60-198)	81-157
C4 Level – mg/dL	31±15 (2-71)	13-39
NIH COVID-19 Severity Scale – no. (%)		
Asymptomatic	0 (0)	
Mild	0 (0)	–
Moderate	0 (0)	
Severe	2 (4)	
Critically Ill	50 (96)	

Figure Legends

Figure 1 – Autoreactive antibody responses in severe COVID-19

(a) Heatmap display of clinical results of 52 SARS-CoV-2 patients with US NIH “severe” or “critical” clinical designations. Patients are organized by ascending CRP values (range 16.5-472.7). Individual testing scale values are indicated following the test name. Of note are the positive tests for serine proteinase 3 but not myeloperoxidase. † – ENA^+ test, anti-RNP; † † – ENA^+ test, anti-centromere. (b) Positive autoantibody test frequency for ANAs (top), RF (middle), or both (bottom) grouped by low (left) or high (right) levels of serum CRP. (c) CRP and ANA titers of (n=7) patients at both initial draw (time point 1) and a two week follow-up (time point 2).

Figure 1


a
CRP (16.5-472.7 pg/mL)
IL-6 (0 - >=100 pg/mL)
ANA (1:80-1:640)
ANA Pattern
RF (14-74 IU)
Serine Proteinase 3 IgG (19-41 CU)
Myeloperoxidase IgG (19-41 CU)
Cardiolipin IgG (20-99.3 CU)
B2GP1 IgG (20-42.3 CU)
Prothrombin IgG (19.9-39.1 CU)
(Sp)
(Nuc)
(Nuc)
(Homo)
(Nuc)
(Nuc)
(Nuc)
(Sp)
(Sp)
(Nuc)
(Nuc)
(Homo)
(Nuc)
(Cent)
(Sp)
(Sp)
(Sp)
(Sp)
(Sp)
(Sp)
(Nuc)
(Sp)
(Sp)
Low CRP (< 144.5 pg/mL)
High CRP (>= 144.5 pg/mL)
Patient with 1 or more serum autoreactivity
Test results above reference range (test-positive)
Test not completed/available
Negative test
Low
High test result
b
Low CRP
High CRP
ANA
RF
Combined
n = 26
n = 26
n = 26
n = 26
n = 25
n = 26
<= 1:40
1:80
1:160
1:320
1:640
RF+
RF-
No autoreactivity
ANA only
RF only
ANA + RF
c
Patient Number
1
2
3
4
5
6
7
CRP (pg/mL)
500
400
300
200
100
0
ANA Titer
2560
1280
640
320
160
80
<= 40
Time Point (2 week follow up)